Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
10:32am, Monday, 13'th Nov 2023
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Growth Stocks to Buy Right Now Without Any Hesitation
06:50am, Saturday, 11'th Nov 2023
AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.
4 Dividend Aristocrats Signal Buys In November As 6 Await
11:27am, Wednesday, 08'th Nov 2023
"Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "-- Kiplinger.com/Investing. 66 Aristocrats, screened as of November 6, 202
Grab these 2 funds with rich 11%-12% yields while you can
07:18am, Wednesday, 08'th Nov 2023
With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.
3 Dividend Stocks That Are Perfect for Beginning Investors
08:41pm, Tuesday, 07'th Nov 2023
While the meme trade phenomenon helped spark interest in the equities sector, passive-income providers generally offer a more solid foundation, thus warranting a closer look at dividend stocks for beg
Guidance leads the market for these stocks; 1 raises, 1 lowers
06:12am, Tuesday, 07'th Nov 2023
Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a marke
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
03:32pm, Monday, 06'th Nov 2023
Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.
3 Spectacular High-Yield Dividend Stocks to Buy in November
10:00am, Sunday, 05'th Nov 2023
AbbVie should be poised to return to rapid growth and recently boosted its dividend. Novartis' spin-off of Sandoz doesn't diminish its attractiveness for income investors.
Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever
05:30am, Saturday, 04'th Nov 2023
Companies with a track record of dividend increases have shown rewarding shareholders is a priority. If those companies also have strong free cash flow, they may offer you a long future of dividend pa
Is AbbVie Stock a Buy Now?
05:32am, Friday, 03'rd Nov 2023
AbbVie's top and bottom lines are struggling, as anticipated. Management thinks this rough patch will be over sometime in 2025.
Meet the Next Trillion-Dollar Companies: Our Top 3 Picks
10:30pm, Thursday, 02'nd Nov 2023
The current five trillion-dollar companies listed on U.S. stock exchanges include Apple (NASDAQ: AAPL ), Microsoft (NASDAQ: MSFT ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), Amazon (NASDAQ: AMZN ), an
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
10:34am, Thursday, 02'nd Nov 2023
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Investor patience tested as pharmaceutical stocks take a tumble
06:07am, Wednesday, 01'st Nov 2023
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:32am, Tuesday, 31'st Oct 2023
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
10:07am, Tuesday, 31'st Oct 2023
Pfizer just got an approval for a drug to treat ulcerative colitis. AbbVie is still trying to consolidate its control over that market.
